The Push for Health Sovereignty

For decades, the pharmaceutical industry relied on a low-cost, highly globalised outsourcing model, repatriating the majority of active pharmaceutical ingredient (API) production to overseas hubs in India and China. However, geopolitical friction and systemic supply chain vulnerabilities have exposed the danger of this dependence. In response, Western European governments and pharmaceutical developers are driving strategic initiatives to onshore API production, prioritizing "Health Sovereignty" and local supply chain resilience.

Yet, onshoring chemical synthesis to Western Europe is not a simple relocation. Higher local labour costs, strict environmental regulations (such as REACH compliance), and high energy overheads mean that European facilities cannot compete on price using legacy batch manufacturing methods. To remain economically viable, Contract Development and Manufacturing Organisations (CDMOs) are investing heavily in automated, next-generation production sites.

Continuous Manufacturing and the Automation Solution

The survival of Western European API manufacturing depends on transitioning from traditional batch processing to continuous manufacturing. Instead of producing chemicals in discrete, labor-intensive batches, continuous flow chemistry runs a constant production stream, offering significant operational advantages:

• Footprint and Efficiency: Continuous manufacturing lines require up to 70% less physical space than batch plants, reducing initial facility capital expenditures.

• Waste and Solvent Reduction: Flow chemistry allows for precise thermal control and mixing, reducing raw material waste and solvent consumption, aligning with European green chemistry mandates.

• Industry 4.0 Integration: Modern facilities are integrating digital twins and real-time release testing (RTRT) directly into continuous production lines, using automated sensors to monitor product quality and adjust parameters dynamically without halting production.

Navigating the Complex Molecule Pipeline

Furthermore, European onshoring is not focused on low-margin commoditised generics, but on high-value, structurally complex molecules. The rapid growth of pipelines dominated by peptides (driven by GLP-1 agonists), antibody-drug conjugates (ADCs), and high-potency APIs (HPAPIs) requires highly specialised containment and synthesis capabilities. European CDMOs are positioning themselves as high-tech partners capable of managing these complex modalities in state-of-the-art facilities located in Switzerland, Germany, and the Netherlands.

Sourcing Leaders for highly Automated CDMO Sites

Running these highly automated, continuous-flow production sites requires a new generation of Site Directors and VP of Manufacturing talent. Legacy chemical plant managers accustomed to manual batch processing are rarely equipped to oversee facilities governed by continuous-process algorithms and advanced digital infrastructure.

RSA prioritises several core competencies when placing manufacturing leaders in European CDMOs:

• Continuous Flow Chemistry Expertise: A proven background in engineering and operating continuous chemical synthesis lines, managing the transition from batch validation to flow chemistry protocols.

• Advanced Automation Stewardship: Experience working with Distributed Control Systems (DCS), Manufacturing Execution Systems (MES), and AI-enabled process monitoring tools.

• European Regulatory and Environmental Fluency: Deep knowledge of EMA manufacturing guidelines, GMP compliance, and local environmental and safety standards (REACH).

The economic viability of European onshoring is ultimately an automation and leadership challenge. By securing site directors who can combine advanced chemical engineering with digital systems oversight, CDMOs can build resilient, high-margin manufacturing hubs that secure the European drug supply chain.